Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 865 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed, Refractory Multiple Myeloma Clear all

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Cabozantinib (XL184); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Dexamethasone, Pelareorep, Pembrolizumab; Drug · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Multiple Myeloma
Interventions: IPI-504; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Hackensack, New Jersey + 1 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cilengitide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Lenalidomide, nab-paclitaxel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: PHE885; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions: TriPRIL CAR T Cells, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: acyclovir, acyclovir sodium, valacyclovir; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 6
States / cities: Duarte, California • Stanford, California • Omaha, Nebraska + 3 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: vorinostat; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
Interventions: Not listed
Lead sponsor: All4Cure; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Jacksonville, Florida • Des Moines, Iowa + 4 more

Conditions: Multiple Myeloma
Interventions: Imetelstat Sodium (GRN163L); Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Buffalo, New York

Conditions: Refractory Multiple Myeloma
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: Perifosine, Lenalidomide, Dexamethasone; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Myeloma
Interventions: Etentamig (ABBV-383); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 21 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Dexamethasone, Lenalidomide, Thalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: P-BCMA-101 CAR-T cells, Rimiducid; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Gilbert, Arizona • Davis, California • San Diego, California + 11 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more

Conditions: Multiple Myeloma
Interventions: Pembrolizumab, Daratumumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Jacksonville, Florida • Atlanta, Georgia • Bloomfield Hills, Michigan

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: lenalidomide; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Opaganib; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: lenalidomide, dexamethasone; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 63
States / cities: Scottsdale, Arizona • Berkeley, California • La Jolla, California + 54 more

Conditions: Multiple Myeloma
Interventions: VELCADE™; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: Bendamustine; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Lymphoma, Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63); Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 63
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more

Search by objective public record fields.

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

TriPRIL CAR T Cells in Multiple Myeloma

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma